Intercept to Present at Upcoming Conferences

Print
| Source: Intercept Pharmaceuticals, Inc.

NEW YORK, May 17, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the following investor conferences:

  • UBS Global Healthcare Conference on May 23, 2017 at 2:30 p.m. Eastern Time
  • Jefferies Healthcare Conference on June 8, 2017 at 2:00 p.m. Eastern Time
  • Goldman Sachs 38th Annual Healthcare Conference on June 13, 2017 at 11:20 a.m. Pacific Time

Webcast information for these events will be available on the Investors page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.

About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.

For more information about Intercept Pharmaceuticals, please contact:
       
Intercept Pharmaceuticals:
Mark Vignola
+1-646-747-1000
investors@interceptpharma.com

Media inquiries: media@interceptpharma.com
Investor inquiries: investors@interceptpharma.com